http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101229995-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2001-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101229995-B1 |
| titleOfInvention | Fusion protein with enhanced erythropoietin activity in vivo |
| abstract | The present invention relates to the in vivo activity of human erythropoietin, in which the carboxy terminal peptide of human chorionic gonadotropin β subunit is fused to the carboxy terminus of human erythropoietin. As to the enhanced fusion protein, the fusion protein retains the intrinsic activity of erythropoietin itself and increases the sugar chain content, thereby dramatically increasing the half-life in vivo while not causing antigenicity in the application of the body. . |
| priorityDate | 2000-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.